Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jadenu versus Exjade for iron chelation in beta thalassemia
IRCT20210831052350N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of deferasirox in beta thalassemia major, beta-thalassemia intermedia and iron overload (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Serum ferritin level, Serum creatinine level and 3 more. Started Nov 2021; status: completed.
02
Drugs
deferasirox
03
Conditions
beta thalassemia majorbeta-thalassemia intermediairon overload
Beyond the preview
Go deeper on IRCT20210831052350N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210831052350N1.